Alendronic Acid/Fosamax daily

When alendronic acid was first licensed in the UK, it was prescribed as a daily tablet. That daily formulation – 10mg taken every morning – remains on the market as a licensed treatment option today, and for certain patients it continues to be the regimen their prescriber determines is most appropriate. Alendronic Acid/Fosamax daily 10mg Tablets are prescribed for the treatment of osteoporosis in postmenopausal women and for the treatment of osteoporosis in men. They represent the original daily dosing schedule for alendronate, predating the introduction of the more widely prescribed 70mg once-weekly formulation.

The daily 10mg regimen is also licensed for the treatment of Paget's disease of bone at a higher dose, though this page covers only the osteoporosis indication. Understanding which formulation and dose a patient has been prescribed, and why, is an important part of managing alendronate treatment safely over time. This medicine is a Prescription Only Medicine. A clinical consultation is required before any supply can take place.

Fosamax is the branded name under which alendronic acid was first brought to market. The 10mg daily tablet is the original formulation of alendronate for osteoporosis. Generic alendronic acid 10mg tablets are bioequivalent and therapeutically interchangeable with the branded Fosamax product.

Alendronic acid is classified as a nitrogen-containing bisphosphonate – a distinction that matters pharmacologically. Nitrogen-containing bisphosphonates, which include alendronate and risedronate, act through a mechanism involving the mevalonate pathway within osteoclast cells. This differs from the mechanism of older, non-nitrogen-containing bisphosphonates. The nitrogen-containing class is characterised by greater potency at the molecular level and is the basis of modern bisphosphonate prescribing for osteoporosis in the UK.

The 10mg daily tablet delivers alendronate to the body in a continuous daily pattern. The total weekly dose of alendronate in the 10mg daily regimen is 70mg – identical to the total delivered by the 70mg once-weekly tablet. Both schedules result in equivalent systemic exposure to the active ingredient over any given week. The choice between them is driven by clinical history, patient preference, and prescriber judgement rather than by any difference in the amount of medicine received.

Prescribers may elect the 10mg daily regimen for specific clinical reasons – for example, where a patient's previous experience, tolerability profile, or clinical context makes the daily schedule a more appropriate choice than the weekly alternative. The prescriber's assessment will take into account the full clinical picture.

Bone has a dual character. It provides mechanical strength and structure, but it is also a metabolically active tissue that participates in mineral homeostasis – particularly the regulation of calcium and phosphate in the body. This means bone is continuously remodelled: old bone is dissolved by osteoclasts and replaced by new bone deposited by osteoblasts.

In osteoporosis, the balance between these two processes shifts in favour of resorption. Bone mineral is lost faster than it can be replaced. The consequence, over months and years, is a progressive reduction in bone mineral density and a structural weakening of trabecular (spongy) bone architecture. This structural deterioration – not simply a loss of density – is what increases fracture risk so markedly in osteoporosis.

Alendronate targets this process at the osteoclast level. After absorption, it binds rapidly and tenaciously to hydroxyapatite at sites of active bone resorption. When osteoclasts attempt to dissolve bone at those sites, they internalise the alendronate. Inside the cell, alendronate inhibits farnesyl pyrophosphate synthase – a key enzyme in the mevalonate pathway – which disrupts the production of lipid molecules essential to osteoclast function. The osteoclast loses cytoskeletal integrity and its ability to resorb bone, and undergoes programmed cell death.

The practical result is a significant slowing of bone turnover. With consistent daily dosing, this effect accumulates over time. Bone mineral density at the spine and hip increases measurably in many patients, and the risk of vertebral and hip fractures is reduced. Clinical evidence for alendronate's fracture risk reduction has been established over decades of use and across multiple large randomised controlled trials, making it one of the most extensively studied medicines in osteoporosis management.

Take one alendronic acid 10mg tablet once every morning, before any food, drink other than plain tap water, or other oral medicines. The timing of the dose in relation to food is not simply a preference – it is a clinical necessity. The oral bioavailability of alendronate is extremely low even under optimal conditions, and the presence of food, beverages, or other medicines in the stomach at the time of dosing can reduce absorption to negligible levels.

Swallow the tablet whole with a full glass of plain tap water – at least 200ml. Do not use mineral water, fruit juice, tea, coffee, milk, or any other drink. Do not take the tablet with a small sip of water; the volume of water matters, both for absorption and for reducing the risk of the tablet lodging in or irritating the oesophagus.

After taking the tablet, remain standing or sitting upright for at least thirty minutes. Do not lie down or return to bed. Alendronate can cause irritation, erosion, or ulceration of the oesophageal lining if it comes into prolonged contact with it. Remaining upright promotes rapid transit of the tablet through the oesophagus into the stomach, substantially reducing this risk. The tablet must not be taken at bedtime or before rising for the day.

Wait at least thirty minutes after taking the tablet before eating breakfast, drinking anything other than plain water, or taking any other oral medicine or supplement. Calcium supplements, antacids, and preparations containing iron, magnesium, or aluminium must be taken at a different time of day – not within thirty minutes of alendronate, and ideally separated by at least two hours.

Take the tablet every day at the same time each morning. If you miss a dose, skip it and take your next dose as usual the following morning. Do not take two doses on the same day to make up for a missed one. Daily dosing requires a consistent morning routine; patients who find it difficult to maintain this should discuss alternatives with their prescriber.

The 10mg Daily Formulation

This product page covers the 10mg daily formulation of alendronic acid. The table below summarises the key parameters of this dosing schedule.

How 10mg Daily Relates to 70mg Once Weekly

As shown in the table above, the 10mg daily and 70mg once-weekly formulations of alendronate deliver an identical total weekly dose of 70mg. The difference is the pattern of delivery. Daily dosing exposes the gastrointestinal tract to the medicine every morning, whereas weekly dosing concentrates that exposure to one morning per week. For some patients, one pattern is tolerated better than the other. Neither schedule provides more alendronate per week than the other.

Clinical note: the 10mg daily formulation is no longer the default prescribing choice in most clinical settings, where the once-weekly 70mg tablet is typically preferred for its simpler adherence profile. However, the 10mg daily formulation retains its UK marketing authorisation and continues to be prescribed where clinically appropriate. The prescribing decision remains with the registered prescriber.

Monitoring and Review

Alendronate therapy for osteoporosis is typically long term and subject to periodic clinical review. National guidelines recommend that prescribers reassess bisphosphonate therapy after an initial treatment period, often three to five years, to evaluate the ongoing benefit-to-risk balance for each individual patient. Bone density monitoring via DEXA scan may form part of this review. Do not stop or alter treatment without first speaking to your prescriber.

Important Note: Always take alendronic acid exactly as prescribed. Do not change your dose or dosing schedule without speaking to your prescriber first.

Daily dosing with alendronate means that any gastrointestinal side effects, if they occur, may be experienced more frequently than with the once-weekly formulation. Understanding this distinction is clinically relevant: patients who develop oesophageal or gastric symptoms on the daily 10mg regimen may find these symptoms more persistent than those occurring with a weekly dose, simply because the medicine is taken every day. Any new or worsening gastrointestinal symptoms should be reported to the prescriber promptly.

Common Side Effects (may affect up to 1 in 10 people)

1. Abdominal pain, bloating, or discomfort
2. Nausea or feeling sick
3. Indigestion, acid reflux, or heartburn
4. Constipation or diarrhoea
5. Musculoskeletal pain, including pain in bones, joints, or muscles
6. Headache

Uncommon Side Effects (may affect up to 1 in 100 people)

1. Oesophageal ulceration, erosion, or stricture – particularly if the tablet is taken without adequate water or without remaining upright
2. Gastric or duodenal ulceration
3. Skin rash, itching, or redness
4. Eye inflammation, including uveitis
5. Low blood calcium (hypocalcaemia), particularly in patients with untreated vitamin D deficiency

Rare and Serious Adverse Effects Requiring Medical Attention

The following adverse effects have been reported with alendronate. They are uncommon but clinically important. Patients should be aware of them and seek medical advice without delay if they develop.

1. Osteonecrosis of the jaw (ONJ): rare deterioration of jaw bone tissue, with risk elevated by invasive dental procedures. Patients must inform their dentist that they are taking alendronate before any planned dental surgery, including tooth extractions, implants, or oral procedures involving bone.
2. Atypical femoral fractures: unusual stress fractures at atypical sites in the thigh bone, reported with prolonged bisphosphonate use. New thigh, hip, or groin pain – particularly if gradual in onset – should be reported to a prescriber promptly. Bilateral pain should also be investigated, as atypical femoral fractures can occur on both sides.
3. Severe musculoskeletal pain: incapacitating bone, joint, or muscle pain has been reported. This may resolve on stopping the medicine, but treatment should not be stopped without medical advice.
4. Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare)

Licensed Indications at 10mg

Alendronic acid 10mg daily is licensed for the treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral and hip fractures, and for the treatment of osteoporosis in men to reduce the risk of fractures. The inclusion of men in the licensed indication is a feature shared with some other alendronate formulations, and it means that this medicine can appropriately be considered for male patients with osteoporosis – a patient group that is sometimes underdiagnosed and undertreated relative to postmenopausal women.

The prescriber will assess the patient's bone density, fracture risk, concurrent conditions, and current medicines before determining whether alendronic acid 10mg daily is appropriate. This assessment may also consider whether the daily schedule is preferable to the once-weekly formulation for that individual patient.

Contraindications and Precautions

Alendronic acid 10mg daily should not be taken by patients with any of the following.

1. Uncorrected hypocalcaemia at the time of commencing treatment
2. Severe renal impairment, defined as creatinine clearance below 35ml per minute
3. Oesophageal abnormalities that impair oesophageal emptying, including stricture and achalasia
4. Inability to stand or sit upright for at least thirty minutes after taking the dose
5. Known hypersensitivity to alendronate or any excipient in the tablet formulation

Patients with active upper gastrointestinal conditions, including oesophagitis, gastric ulcers, or recent gastrointestinal surgery, should inform their prescriber before starting alendronate. These conditions may represent a contraindication or require careful clinical evaluation before treatment begins.

Alendronate is not recommended during pregnancy or breastfeeding. It is not licensed for children or adolescents. Patients with mild to moderate renal impairment do not require dose adjustment but should inform their prescriber, as renal function may affect ongoing prescribing decisions.

Alendronic acid 10mg daily is a Prescription Only Medicine. Completing a clinical consultation is the first and essential step in this process. A prescription is a possible outcome of the consultation, not a guaranteed result. The prescriber will issue a prescription only where they are satisfied, on the basis of your individual clinical information, that this medicine is appropriate for you.

During your consultation with Pharmacy Planet, a UK registered prescriber will review the information you provide about your diagnosis, bone health history, any previous fractures, current and recent medicines, and relevant medical conditions. If you are a patient being prescribed alendronate for the first time, the prescriber will assess your suitability for this class of medicine and, where relevant, whether the daily 10mg formulation is preferable to alternative alendronate schedules.

Patients with an established osteoporosis diagnosis who have been prescribed alendronic acid 10mg daily by their GP or specialist and are seeking a convenient route for ongoing supply will also need to complete a consultation. The prescriber will confirm that continued treatment remains appropriate and that no new clinical information has emerged that would change the prescribing decision.

Where the prescriber requires additional clinical information before making a prescribing decision – for example, a recent bone density result or confirmation of renal function – you will be informed and guided accordingly. Our pharmacy team is available to assist with queries at any stage of the process.

Store alendronic acid 10mg tablets below 25 degrees Celsius. Keep them in their original packaging, away from moisture and direct light. The tablets should not be stored in a bathroom cabinet or near a kitchen sink, where humidity and temperature fluctuation are common.

Because the 10mg daily formulation is taken every morning, a daily habit can make it easy to forget to check the remaining supply. Check the pack regularly and ensure you have a sufficient supply to avoid unplanned gaps in treatment. Gaps in bisphosphonate therapy reduce its protective effect.

Do not use tablets past their expiry date. The date printed on the packaging refers to the last day of the month stated. Return any unused or expired tablets to a pharmacy for safe disposal. Medicines must not be placed in household waste or washed into drains.

All seven medicines listed below are oral tablets or capsules prescribed for osteoporosis, the same therapeutic category and the same form factor, making direct comparison appropriate. They differ in their active ingredient, dosing frequency, licensed indication, and mechanism of action.

The table below compares commonly prescribed oral bisphosphonate treatments available through Pharmacy Planet's osteoporosis service. Products are listed in order of dosing frequency, from daily to monthly, so you can quickly identify how each medicine fits into a patient's routine.

Important: This comparison is for general information only and does not replace medical advice. A prescriber will decide which treatment is suitable for you following an online consultation. All medicines listed are Prescription Only Medicines (POMs). Suitability depends on individual clinical circumstances including diagnosis, renal function, medical history, and concurrent medicines.

Pharmacy Planet is a GPhC-registered online pharmacy providing prescription medicines to patients across the UK within a regulated, clinically governed framework. All prescriptions we dispense are reviewed by a qualified pharmacist before dispatch, and our clinical processes are aligned with NHS guidance and GPhC standards for online pharmacy practice.

For patients managing osteoporosis with a daily medicine, reliable and consistent access to supply is important. A missed week of daily bisphosphonate treatment, caused by a delay in obtaining a repeat prescription, represents a real gap in bone protection. Our consultation and dispensing service is designed to give patients a dependable, straightforward route to their ongoing prescription.

We take patient safety seriously at every stage – from the prescriber's clinical review of your consultation to the pharmacist's final check before your medicine is dispatched. Our team is available to answer questions about your treatment and to support you throughout your care with us.

1. electronic Medicines Compendium (emc). Fosamax 10mg Tablets / Alendronic Acid 10mg Tablets – Summary of Product Characteristics. www.medicines.org.uk/emc. Accessed June 2026.
2. British National Formulary (BNF). Alendronic acid. bnf.nice.org.uk/drugs/alendronic-acid. Accessed June 2026.
3. NHS. Alendronic acid. www.nhs.uk/medicines/alendronic-acid. Accessed June 2026.
4. National Osteoporosis Guideline Group (NOGG). Clinical Guideline for the Prevention and Treatment of Osteoporosis. www.nogg.org.uk. Accessed June 2026.
5. Black DM, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535-1541.